Author Affiliations: Department of Bioethics (Dr Goldenberg) and Center for Genetic Research Ethics and Law (Drs Goldenberg and Sharp), Case Western Reserve University School of Medicine, Cleveland, Ohio; and Department of Bioethics, Center for Ethics, Humanities and Spiritual Care, and Genomic Medicine Institute, Cleveland Clinic, Cleveland, Ohio (Dr Sharp).
Advances in next-generation sequencing technologies have the potential to spur better integration of genetic testing into patient care. Appropriate utilization of these technologies will require the capacity to manage, interpret, and communicate large amounts of personal genetic information.1 Because the clinical infrastructure necessary to support these activities is currently limited,2 it is likely that the earliest applications of whole-genome sequencing will be restricted to settings in which genetic testing is already a routine part of clinical or public health practice, such as state newborn screening (NBS) programs.
Goldenberg AJ, Sharp RR. The Ethical Hazards and Programmatic Challenges of Genomic Newborn Screening. JAMA. 2012;307(5):461–462. doi:10.1001/jama.2012.68
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: